Tag Archives: Unilever

Unilever names former Heinz exec Schumacher as CEO

  • To become CEO July 1
  • Activist shareholder says met Schumacher when at Heinz
  • First outsider CEO since Paul Polman appointed in 2008
  • Unilever shares outpace FTSE 100

LONDON, Jan 30 (Reuters) – Unilever on Monday appointed Hein Schumacher to replace Alan Jope as chief executive from July in a move that was welcomed by investors including board member and activist shareholder Nelson Peltz.

Schumacher, 51, rejoined Unilever in October last year as non-executive director and is currently the chief of Dutch dairy business FrieslandCampina.

He worked at Unilever more than 20 years ago before working for retailer Royal Ahold NV and packaged food maker H.J. Heinz in the United States, Europe and Asia.

One of the biggest consumer companies in the world with more than 400 brands ranging from detergent to ice cream, Unilever said in September said that Jope planned to retire at the end of 2023.

Billionaire activist investor Nelson Peltz, who heads investor Trian Partners, said he strongly supports Schumacher “as our new CEO and look(s) forward to working closely with him to drive significant sustainable stakeholder value.”

Peltz become a Unilever board member in July after it was revealed early last year that he had built a stake in the company.

“I first met Hein when I served as a director at the H.J. Heinz Company from 2006 to 2013 and was impressed by his leadership skills and business acumen,” Peltz said.

Peltz, through his Trian Fund, holds a nearly 1.5% stake in Unilever, making him the fourth largest shareholder, according to Refinitiv Eikon data.

Unilever shares were up 0.56% versus a FTSE 100 (.FTSE) index down 0.1% as of 1032 GMT.

The move was also cheered by other investors and analysts, who have felt in recent years that Unilever needed an outsider’s touch.

“Positive that he’s an external appointment,” Jack Martin, a fund manager at Unilever shareholder Oberon Investments, said. “Good CV from what I read, hopefully provides the impetus the company requires.”

‘ESG SAVVY, PRAGMATIC’

Unilever’s shares have underperformed European consumer staples and discretionary indices during CEO Jope’s tenure, which began in January 2019.

Reuters Graphics

His failed bids for GlaxoSmithKline’s (GSK.L) consumer healthcare business last year lost him some good faith among investors, including influential British billionaire Terry Smith, owner of Fundsmith.

Smith said at the time that Jope needed to focus less on sustainbility and more on building Unilever’s core business.

“Hein is ideal for Unilever — he’s got roots at the company but at the same time he’s external,” Allan Leighton, former CEO of British food retailer Asda and ex-chair of Britain’s Royal Mail, told Reuters.

Leighton, who worked with Schumacher on the board of C&A AG, described him as “ESG savvy but in a pragmatic and commercial way.”

Tineke Frikee, a fund manager at Unilever shareholder Waverton Investment Management, said: “It is good Schumacher has plenty of industry experience outside Unilever, particularly international.”

“I note though that his background is mainly in food, rather than beauty and personal care. This may lead the market to reduce the probability of a potential food spin-off.”

Unilever’s food business includes Ben & Jerry’s ice cream, Colman’s mustard, Hellman’s mayonnaise and Knorr stock cubes.

Some investors and analysts have speculated over the past year that Unilever might spin off what they feel is a weaker food business to focus on personal goods, beauty and home care.

“Why hire a food exec, if you are planning to sell the food business?” Bernstein analyst Bruno Monteyne said, adding that selling the food business “will always be on the cards, but I doubt that it is top priority in the short term.”

But Monteyne pointed out that some investors were hoping Unilever would name someone more well-established, globally.

“Investors we spoke to in recent weeks were hopeful for a more familiar name from a successful U.S.-based FMCG (fast-moving consumer goods) turnaround.”

Unilever had been considering internal and external candidates for the role.

Sources told Reuters in October that the candidates included finance chief Graeme Pitkethly, personal care division boss Fabian Garcia and Hanneke Faber, who heads the company’s nutrition group.

Reporting by Yadarisa Shabong and Richa Naidu; editing by Matt Scuffham and Jason Neely

Our Standards: The Thomson Reuters Trust Principles.

Richa Naidu

Thomson Reuters

London-based reporter covering retail and consumer goods, analysing trends including coverage of supply chains, advertising strategies, corporate governance, sustainability, politics and regulation. Previously wrote about U.S. based retailers, major financial institutions and covered the Tokyo 2020 Olympic Games.

Read original article here

Prices have not peaked yet, says Unilever CEO

Unilever CEO Alan Jope photographed at the World Economic Forum in May 2022.

Hollie Adams | Bloomberg | Getty Images

The CEO of consumer goods giant Unilever said Tuesday that prices would likely continue to rise in the near term, adding that his firm had a playbook for high inflation thanks to its business dealings in markets like Argentina and Turkey.

Speaking to CNBC’s Joumanna Bercetche at the World Economic Forum in Davos, Switzerland, Alan Jope talked about how his firm was managing its operations in the current climate.

“For the last 18 months we’ve seen extraordinary input cost pressure … it runs across petrochemical derived products, agricultural derived products, energy, transport, logistics,” he said.

“It’s been feeding through for quite some time now and we’ve been accelerating the rate of price increases that we’ve had to put into the market,” he added.

“So far, the consumer response in terms of volume softness has been very muted, the consumer has been very resilient,” Jope said.

“We do see the prospect of higher volume elasticity as winter energy costs hit, as households’ savings levels come down and that buffer goes away and as prices continue to rise,” he said.

Last October, Unilever published its third-quarter results for 2022, with the firm reporting price growth of 12.5%.  

Jope was asked if he foresaw any moderation when it came to inflationary pressures. “It’s very hard to predict the future of commodity markets,” he replied.

“Even if you press the oil major CEOs, they’ll be a little cagey on giving an outlook on energy prices.”

Unilever’s view, he said, was that “we know for sure there’s more inflationary pressure coming through in our input costs.”

“We might be, at the moment, around peak inflation, but probably not peak prices,” he went on to state.

“There’s further pricing to come through, but the rate of price increases is probably peaking around now.”

Stock picks and investing trends from CNBC Pro:

Unilever has a global footprint and owns brands including Ben & Jerry’s, Magnum and Wall’s.

During his interview with CNBC, Jope touched upon the international dimension of his business and how the experience of operating in a range of markets was steering it through the current climate.  

“Nobody running a business at the moment has really lived through global inflation, it’s a long time since we’ve had global inflation,” he said.

“But we’re used to high levels of inflation from doing business in places like Argentina, or Turkey, or parts of Southeast Asia,” he added.

“So we do have a playbook, and the playbook is that it’s important to protect the shape of the P&L by landing price.”

“And so it’s not that we’ve taken more price, we just started acting earlier than many of our peers, and the guidance that we’ve been getting from our investors is they support that and feel that that’s an appropriate action.”  

This, Jope explained, was “something we have learned from being in these high inflationary markets, though … much of that inflation is currency weakness, historically.”

“But now those markets are having to deal with the combination of commodity pressure and currency weakness. So our instinct is to act quickly when costs start coming through.”

Read original article here

Dry shampoo recall list: Unilever recalls Dove, Bed Head, more hair care products over cancer-causing chemical benzene

Unilever voluntarily recalled products from brands such as TRESemme, Suave, Dove and more due to concerns about benzene.

Unilever recently announced a voluntary recall of 19 popular dry shampoo aerosol products sold in the United States due to concerns about benzene, a chemical known to cause cancer.

Exposure to benzene, which is classified as a human carcinogen, can occur through inhalation, ingestion, or through skin contact and can result in cancers including leukemia and blood cancers, according to the U.S. Department of Health and Human Services.

Humans are exposed to benzene daily through things like tobacco smoke and detergents, but exposure can be considered dangerous depending on the dose and duration of contact, according to the Centers for Disease Control and Prevention.

Unilever said that it is pulling the products “out of an abundance of caution” and that the company has not yet received any reports of adverse event relating to the recall to date.

SEE ALSO: Hair-straightening chemicals may be linked to uterine cancer risk, study finds

The recalled products were produced before October 2021 and retailers have been notified to pull the affected products from shelves.

A complete list of the affected products and consumer codes can be found here. No other products from Unilever or its brands are impacted by this recall, the company stated in a press release.

The list of affected products include:

Dove

  • Dove Dry Shampoo Volume and Fullness
  • Dove Dry Shampoo Fresh Coconut
  • Dove Dry Shampoo Fresh and Floral
  • Dove Dry Shampoo Ultra Clean
  • Dove Dry Shampoo Invisible
  • Dove Dry Shampoo Detox and Purify
  • Dove Dry Shampoo Clarifying Charcoal
  • Dove Dry Shampoo Go Active

Nexxus

  • Nexxus Dry Shampoo Refreshing Mist
  • Nexxus Inergy Foam Shampoo

Suave

  • Suave Dry Shampoo Hair Refresher
  • Suave Professionals Dry Shampoo Refresh and Revive

TRESemmé

  • TRESemmé Dry Shampoo Volumizing
  • TRESemmé Dry Shampoo Fresh and Clean
  • TRESemmé Pro Pure Dry Shampoo

Bed Head

  • Bed Head Oh Bee Hive Dry Shampoo
  • Bed Head Oh Bee Hive Volumizing Dry Shampoo
  • Bed Head Dirty Secret Dry Shampoo

Rockaholic

  • Bed Head Rockaholic Dirty Secret Dry Shampoo

The recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Unilever urged consumers to stop using the affected aerosol dry shampoo products immediately and visit the company website for eligible product reimbursements.

Copyright © 2022 ABC News Internet Ventures.



Read original article here

Dry shampoo recall list: Unilever recalls Dove, Bed Head, more hair care products over cancer-causing chemical benzene

Unilever voluntarily recalled products from brands such as TRESemme, Suave, Dove and more due to concerns about benzene.

Unilever recently announced a voluntary recall of 19 popular dry shampoo aerosol products sold in the United States due to concerns about benzene, a chemical known to cause cancer.

Exposure to benzene, which is classified as a human carcinogen, can occur through inhalation, ingestion, or through skin contact and can result in cancers including leukemia and blood cancers, according to the U.S. Department of Health and Human Services.

Humans are exposed to benzene daily through things like tobacco smoke and detergents, but exposure can be considered dangerous depending on the dose and duration of contact, according to the Centers for Disease Control and Prevention.

Unilever said that it is pulling the products “out of an abundance of caution” and that the company has not yet received any reports of adverse event relating to the recall to date.

SEE ALSO: Hair-straightening chemicals may be linked to uterine cancer risk, study finds

The recalled products were produced before October 2021 and retailers have been notified to pull the affected products from shelves.

A complete list of the affected products and consumer codes can be found here. No other products from Unilever or its brands are impacted by this recall, the company stated in a press release.

The list of affected products include:

Dove

  • Dove Dry Shampoo Volume and Fullness
  • Dove Dry Shampoo Fresh Coconut
  • Dove Dry Shampoo Fresh and Floral
  • Dove Dry Shampoo Ultra Clean
  • Dove Dry Shampoo Invisible
  • Dove Dry Shampoo Detox and Purify
  • Dove Dry Shampoo Clarifying Charcoal
  • Dove Dry Shampoo Go Active

Nexxus

  • Nexxus Dry Shampoo Refreshing Mist
  • Nexxus Inergy Foam Shampoo

Suave

  • Suave Dry Shampoo Hair Refresher
  • Suave Professionals Dry Shampoo Refresh and Revive

TRESemmé

  • TRESemmé Dry Shampoo Volumizing
  • TRESemmé Dry Shampoo Fresh and Clean
  • TRESemmé Pro Pure Dry Shampoo

Bed Head

  • Bed Head Oh Bee Hive Dry Shampoo
  • Bed Head Oh Bee Hive Volumizing Dry Shampoo
  • Bed Head Dirty Secret Dry Shampoo

Rockaholic

  • Bed Head Rockaholic Dirty Secret Dry Shampoo

The recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Unilever urged consumers to stop using the affected aerosol dry shampoo products immediately and visit the company website for eligible product reimbursements.

Copyright © 2022 ABC News Internet Ventures.



Read original article here

Procter & Gamble Sounds a Warning After Strong Quarter

Procter & Gamble Co.

PG -6.18%

, maker of Tide detergent and Pampers diapers, is predicting the slowest sales growth in years as consumer belt-tightening is beginning to hit household staples.

The outlook comes after the Cincinnati-based consumer-products giant on Friday reported its biggest annual sales increase in 16 years because of the price increases that it placed on mainstays from toothpaste to toilet paper.

P&G’s organic sales, a closely watched metric that strips out deals and currency moves, rose 7% for the year ended June 30, the most since 2006. Shoppers paid substantially higher prices.

But consumers are beginning to cut back amid mounting inflation, executives said. They are using up products they stockpiled during the pandemic or holding off on replenishing supplies. Sales volumes declined 1% in the most recent quarter.

“For us, the downturn is not yet visible,” P&G finance chief

Andre Schulten

said. “We’re also not naive, we see the pressure on the consumer.”

P&G expects organic sales growth of 3% to 5% for the current year, the lowest since 2019 when the company notched a 5% increase. The company predicts consumer-goods industry growth will slow by a percentage point or more from the last fiscal year’s 5% growth.

P&G Chief Executive

Jon Moeller

said in an interview that consumers are beginning to shift to cheaper, private-label alternatives, a trend already under way in food and beverages. He called the shift small but noticeable.

Mr. Moeller said he is confident that growth, though more muted relative to the past few years, will remain solid as high employment levels coupled with healthy household balance sheets enable consumers to keep spending on necessities while they cut costs elsewhere.

“There is no inherent reason why people are just going to stop buying modestly priced consumer products, daily-use essentials where performance matters,” he said. “You have to look elsewhere to get signals of consumer stress.”

The consumer-sentiment index and the consumer-confidence index both try to measure the same thing: consumers’ feelings. WSJ explains why the Federal Reserve is keeping a close eye on consumer confidence in 2022. Illustration: Adele Morgan

P&G shares fell more than 6%.

P&G’s results and outlook largely echo the messages coming from other big consumer brands. Companies including

Coca-Cola Co.

,

McDonald’s Corp.

and

Kimberly-Clark Corp.

this week reported sales gains driven by higher prices, and executives said they would keep passing along increased costs to shoppers for now. Yet some executives also said consumers are starting to show signs of stress, trading down to cheaper brands or cutting back on how much they buy.

The world’s biggest consumer packaged goods company by sales, P&G has largely outpaced competitors amid the pandemic, especially in the U.S.

Rivals are showing signs of gaining ground.

Colgate-Palmolive Co.

on Friday said it now expects bigger-than-expected organic sales gains, predicting an increase of 5% to 7% for the calendar year, up from 4% to 6%. Last week,

Kimberly-Clark

and

Unilever

PLC also raised sales outlooks for the calendar year.

Church & Dwight Co.

Chief Executive

Matthew Farrell

said on Friday that demand is accelerating for low-cost laundry detergent, while people are giving up electric toothbrushes for manual options. “Consumers are making choices to make their budget stretch further,” he said.

A central question is how consumers and retailers respond to further price increases. P&G said Friday that it had announced to retailers another round of price increases, in mid-single-digit percentages, which will take effect toward the end of summer.

SHARE YOUR THOUGHTS

How do you feel about the strength of the economy now? Join the conversation below.

P&G, after more than four years of market-share gains, lost share in the four-week period ended July 16 compared with a year ago, Bernstein analyst Callum Elliott said in a research note analyzing retail data. Losses are in every category except for beauty, he said.

“While prices spiral, the consumer also continues to adjust to the new reality,” he said.

Mr. Moeller said P&G continues to gain market share broadly in the U.S. and globally.

Organic sales rose 7% in the quarter ended June 30, with prices up 8% on average. P&G attributed the 1% decline in sales volume primarily to Covid-related shutdowns in China and intentional downsizing of its business in Russia amid the war in Ukraine.

P&G reported $19.5 billion in revenue for the quarter, up 3% from a year ago. Diluted net earnings per share were $1.21, up 7%.

The company expects diluted net earnings per share will be between flat and up 4% for the fiscal year as it faces an anticipated $3.3 billion hit tied to foreign-exchange rates and higher costs for materials and freight.

Write to Sharon Terlep at sharon.terlep@wsj.com

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here

Ben & Jerry’s sues Unilever to block sale of Israeli business

The Vermont-based ice cream maker filed a complaint Tuesday in the US District Court in New York, where it sought an injunction against Unilever (UL) “to protect the brand and social integrity Ben & Jerry’s has spent decades building.”

Ben & Jerry’s has been doing business in Israel since 1987, but in recent years it had come under pressure for selling in West Bank settlements, considered illegal under international law. In July 2021, it announced it would stop selling in the West Bank altogether.

That triggered a dispute with its longtime distributor in Israel, American Quality Products (AQP), which sued Ben & Jerry’s and Unilever in March, arguing that they were “unlawfully terminating its 34-year business relationship in order to boycott Israel.”

Unilever, one of the world’s top sellers of consumer goods including Dove soap and Magnum ice cream, tried to draw a line under the controversy with its announcement last week that it had sold Ben & Jerry’s Israeli business for an undisclosed amount to AQP.

The retail giant said that going forward, Ben & Jerry’s would be sold under its Hebrew and Arabic names throughout Israel and the West Bank.

But that decision to sell to AQP took the board of Ben & Jerry’s by surprise, according to its court filing, which said that its chair had been “stunned” to hear the news.

Since 2021, Ben & Jerry’s has been fiercely opposed to the sale of its products in the West Bank, saying that it would be “inconsistent with” the brand.

In its complaint Tuesday, it noted that its brand values are legally overseen by an independent board of directors under a 2000 agreement with Unilever.

The board decided to pursue legal action last week at a meeting where five directors voted to authorize litigation, and two appointees from Unilever dissented, Ben & Jerry’s said.

In a statement last week, Unilever acknowledged that “Ben & Jerry’s and its independent board were granted rights to take decisions about its social mission.”

But it maintained that the parent company “reserved primary responsibility for financial and operational decisions, and therefore has the right to enter this arrangement.”

In a new statement Wednesday, a Unilever spokesperson reiterated that it “had the right to enter this arrangement.”

“The deal has already closed,” the representative said, adding that it would not comment on pending litigation.

In its statement last week, Unilever said that it had conducted a review of its business there “over several months, including with the Israeli government.”

“Unilever has used the opportunity of the past year to listen to perspectives on this complex and sensitive matter and believes this is the best outcome for Ben & Jerry’s in Israel,” it added.

— Jordan Valinsky contributed to this report.

Read original article here

Ben & Jerry’s sues parent company Unilever over sale of Israeli business

A tub of Ben and Jerry’s ice cream, manufactured by Unilever Plc.

Chris Ratcliffe | Bloomberg | Getty Images

Ben & Jerry’s is suing parent company Unilever to stop the sale of its Israeli business to a local licensee, a move the consumer products giant said would keep the ice cream products available in Israel and its occupied territories.

Ben & Jerry’s said in a lawsuit filed in federal court in New York Tuesday that Unilever’s decision was made without the approval of its independent board, which has the primary responsibility for safeguarding the integrity of its brand’s name.

A judge on Tuesday denied Ben & Jerry’s application for a temporary restraining order but ordered Unilever to show cause by July 14 for why a preliminary injunction should not be issued. 

Representatives for Unilever and Ben & Jerry’s did not immediately respond to requests for comment.

The suit marks the latest development in a controversy that was set off last year when Ben & Jerry’s said it would stop sales in the West Bank territory occupied by Israel since the Six Day war in 1967.

Israel’s government sees the occupied territories as part of its economy and any efforts to boycott business in the areas are seen as applying to the country. Stopping sales of the ice cream in the occupied territories would have ended sales throughout Israel.

In its suit, Ben & Jerry’s said that its brand is “synonymous with social activism” and that as part of its deal to be acquired by Unilever in 2000, it had reserved the “primary responsibility for safeguarding the integrity” of the Ben & Jerry’s brand through its independent board.

It said that Unilever had publicly recognized the brand’s right to make decisions about its social mission. But then last week, Ben & Jerry’s said Unilever “abruptly reversed course.” 

Unilever announced last week that it sold the Israeli branch of its Ben & Jerry’s business to American Quality Products, which licenses the ice cream products in Israel. American Quality said it would continue selling Ben & Jerry’s under Hebrew and Arabic names throughout Israel and its occupied territories. 

Despite the right of Ben & Jerry’s independent board to make decisions about the brand’s social mission, Unilever said in announcing the sale that it had the right to enter into the agreement because it had reserved primary responsibility for financial and operational decisions.

After Unilever announced the sale, Ben & Jerry’s said in its lawsuit that its board held a special meeting on Friday and voted to sue over the decision.

In an interview with CNBC after last week’s move by Unilever the Israeli licensor, Avi Zinger of American Quality Products, said any potential lawsuit would be “between Unilever and Ben & Jerry’s. I already have a deal.”

— CNBC’s Candice Choi contributed to this report.

Read original article here

Unilever, Peloton and Kohl’s Become Targets of Activist Investors

When a company’s stock starts to drag, activist investors often swoop in to shake things up, pressuring the laggard to cut costs, shed poorly performing assets or even consider selling itself altogether.

Sensing opportunity for investment profits at a time when the stock market has been rocky, activists have taken aim at their latest targets: the multinational consumer goods company Unilever, the fitness equipment maker Peloton and the department store chain Kohl’s.

Shares in Unilever rose more than 6 percent on Monday on the revelation that Trian Fund Management, the investment firm founded by Nelson Peltz, has amassed a stake in the consumer products giant.

The emergence of Mr. Peltz in Unilever’s stock, previously confirmed by people briefed on the matter, poses another challenge for the company, days after it was forced to drop its $68 billion takeover bid for GlaxoSmithKline’s consumer health business.

It is unclear how much of a stake Trian owns or what it is calling for. But Mr. Peltz is one of Wall Street’s most prominent activist investors, who has successfully pushed for change at consumer goods companies like Mondelez and Procter & Gamble. His successful battle to win a seat on Procter & Gamble’s board in 2017 was the costliest such fight on record.

Shareholders and analysts appear to be hoping that Trian will prod Unilever into selling lower-growth brands, something that Mr. Peltz has pushed companies to do in the past.

But others warned that even Mr. Peltz may not be able to improve the company’s fortunes anytime soon. “The changes required to culture and structure will take time and may fail, as they have done previously,” Bruno Monteyne, an analyst at Bernstein, wrote to clients on Monday. “Unilever stock is likely to be an emotional trading stock for years.”

In a letter to the embattled at-home fitness equipment maker, Blackwells Capital called for directors to fire the company’s chief executive, John Foley, who is also a co-founder, and to weigh a sale as its shares tumble amid falling sales and growing inventory. Peloton said last week it was considering layoffs and “resetting” its production levels for “sustainable growth.” The stationary bike company initially had to ramp up production to meet pandemic demand — and has now found itself with excess inventory as more people head outdoors for their fitness.

Peloton is “on worse footing today than it was prior to the pandemic,” Blackwells wrote. “With high fixed costs, excessive inventory, a listless strategy, dispirited employees and thousands of disgruntled shareholders.”

Shares of Peloton have tumbled more than 80 percent over the past year, giving it a market capitalization of a little over $9 billion. Shares were up more than 4 percent in morning trading.

Still, any fight might be an uphill battle: Peloton has two shares of stock, where Class B shareholders have drastically more voting power — and Mr. Foley alone controls nearly 40 percent of shareholder votes. A representative for Peloton did not immediately respond to a request for comment.

The retailer Kohl’s has received a roughly $9 billion offer to go private in a deal with an investment consortium backed by the activist hedge fund Starboard Value, according to two people familiar with the matter. The private equity firm Sycamore Partners has also reached out to Kohl’s about a potential deal.

Kohl’s confirmed on Monday that it had “received letters expressing interest in acquiring” the company. Its shares are up more than 30 percent in early trading.

Kohl’s is already under pressure to improve its share price. The activist firm Macellum Advisors, which has a 5 percent stake in Kohl’s, urged the retailer in a letter last Tuesday to explore strategic alternatives, including a sale. That move came after Macellum raised similar criticisms over Kohl’s stock performance last year. The hedge fund Engine Capital has also been calling on Kohl’s to consider a sale, along with other strategic initiatives.

But it is not clear whether Kohl’s will approve a sale, which would depend on whether the initial suitors can secure the necessary financing.

Starboard has helped Acacia Research Corporation, which is leading the consortium’s bid, to raise equity to pay for its offer. Acacia has also received a letter of confidence from a bank pledging support for arranging debt. It is in talks with a firm that would sell off part of Kohl’s real estate to help fund the bid, in what is likely to result in a “sale-and-lease-back” transaction, in which a company leases back the real estate it has sold.

Such sale-lease-back deals have worked at companies like Bed Bath & Beyond, but they have fared poorly for others like Sears, because the cost of rent can limit the company’s ability to spend on capital investment. They also often entail long-term leases, which could lock Kohl’s in to property at a time it needs to be nimble.

Kohl’s said last year that various covenants inhibited its ability to do such deals. It also said moves like those could threaten its investment grade status.

“We think adding fixed costs as margins hit multiyear highs and are at risk of retrenchment is risky, and we are wary of the rent expense that Kohl’s would have to shoulder through a full cycle,” analysts at Bank of America wrote about a potential lease-back.

Read original article here

Unilever CEO Misses Out on Advil Just as He May Need It

(Bloomberg) — Unilever Plc Chief Executive Officer Alan Jope faces growing pressure to deliver a new strategy after investor dissent forced the Dove soap owner to walk away from a bid for GlaxoSmithKline Plc’s consumer products division.

Most Read from Bloomberg

Unilever on Wednesday abandoned its 50 billion-pound ($68 billion) pursuit of a business that includes brands like Sensodyne toothpaste and Advil painkiller, after the U.K. drugmaker rejected its approaches and Unilever’s share price plunged.

The very public defeat, which came after analysts implored Unilever not to proceed and a big shareholder said management had “lost the plot,” was a flashback to Kraft Heinz Co.’s failed bid to acquire the company in 2017 for $143 billion. That debacle prompted radical changes at Unilever, including consolidating its headquarters in the U.K., ditching a cumbersome Anglo-Dutch structure, and adopting a more aggressive acquisition strategy that’s failed in its first big test.

A deal for the Glaxo brands would’ve been Unilever’s largest ever takeover and was intended to anchor the company’s pivot to focus on consumer health-care. Jope set out that ambition internally after the shift to London in 2020, which was meant to facilitate major acquisitions and disposals.

Unilever shares extended their relief rally on Thursday, rising 1.9% in early London trading. Glaxo’s stock dropped 1.4%.

Earlier this week, Unilever said the Glaxo division was a “strong strategic fit,” but that it would explore other takeover opportunities in consumer health. The company also said it would maintain financial discipline and wouldn’t overpay.

Health, Beauty

In that statement, Jope also announced a revamp of Unilever that would refocus around its health, beauty and hygiene operations, predicated on major acquisitions, and suggesting divestitures may involve its food operations.

In recent years, that arm of the company has been wounded by inflationary pressures in emerging markets that have slowed Unilever’s overall growth compared with archrival Nestle SA, which gets a boost from its successful pet food business.

Still, Unilever’s share price fell sharply as investors questioned the rationale for the Glaxo deal. Analysts wrote notes titled “Please Don’t” and described it as a “very bad deal.” Ratings agencies also warned about a possible downgrade of Unilever’s credit rating if it went ahead with a takeover.

Jope was already facing criticism from some shareholders for a focus on sustainability as the company’s stock price languished.

‘Damage Limitation’

It’s “good news” that the deal won’t happen, Bernstein analyst Bruno Monteyne said, though he described the latest move as an effort at “damage limitation.”

Unilever is “trying to control the narrative,” he said in an email. “By ruling out a higher bid, it looks like they end the offer here. That is obviously not the case. Investors stopped the bid through the share price and the feedback they gave.”

Unilever’s move to abandon the pursuit also raises questions over the strategy of Glaxo CEO Emma Walmsley, who has said she favors plans to spin off the consumer division. The drugmaker has said it would consider any offers, after Elliott Investment Management LP pushed her to boost shareholder returns, and new bidders could emerge.

In response to Unilever’s earlier interest, Glaxo had said it expects the consumer unit to see sales grow 4% to 6% in the medium term, faster than the market rate. The estimate raises the bar for any other prospective buyers, amid expectations that a successful overture could require a top-up of $10 billion or so. Glaxo will set out the rationale for such growth at an investor meeting at the end of February.

Other Bidders?

“We are strongly focused on maximizing shareholder value and are very confident in the future of the business and its potential,” a Glaxo spokesperson said. “The consumer health-care business has an exceptional portfolio and offers existing and prospective shareholders a highly attractive financial profile supporting investment and future returns.”

Unilever’s pursuit of the unit had sparked speculation about other suitors emerging, including Procter & Gamble Co. or Nestle SA.

When analysts pressed P&G about its acquisition strategy on Wednesday, Chief Executive Officer Jon Moeller said he likes the current portfolio and will be “very disciplined” on any deals. Skin care and personal healthcare are the two categories that P&G considers particular focus areas for potential deals, he said on a call, but “we don’t need large M&A to deliver” on financial targets.

(Updates with Unilever and Glaxo shares in fifth paragraph)

Most Read from Bloomberg Businessweek

©2022 Bloomberg L.P.

Read original article here

Dove soap maker Unilever signals pursuit of GSK consumer arm; shares fall

  • Unilever shares fall over 8%, GSK gains
  • Unilever signals it would pursue deal for GSK unit
  • Says committed to ‘strict financial discipline’

Jan 17 (Reuters) – Unilever (ULVR.L) signalled on Monday it would pursue a deal for GSK’s (GSK.L) consumer business, calling it a “strong strategic fit”, but Unilever shares slid more than 8%, highlighting investors’ doubts about its 50-billion-pound ($68.4 billion) offer.

GlaxoSmithKline confirmed over the weekend that it had rejected three bids from the Dove soap maker for the consumer healthcare business, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller.

GSK, led by Emma Walmsley, has hired Goldman Sachs (GS.N) and Citigroup (C.N) to review Unilever’s approach but it will not engage in talks unless Unilever bumps up its offer, sources familiar with the matter said.

Register now for FREE unlimited access to Reuters.com

Register

GSK’s shares jumped 6% to their highest level since May 2020. It said on Saturday Unilever’s proposal “fundamentally undervalued” the consumer business, adding that it would stick to its plan of listing the division this year.

“Initial feedback on the deal from investors over the weekend has been almost uniformly negative,” Jefferies analysts said in a note. Others noted Unilever’s share price fall indicated a lack of confidence in its management and concern over the price.

The Marmite spread maker, however, defended the bid for the GSK consumer business, in which U.S. drugs company Pfizer (PFE.N) owns a 32% stake.

“The acquisition would create scale and a growth platform for the combined portfolio in the U.S., China and India, with further opportunities in other emerging markets,” Unilever said, pointing to synergies in the oral care and vitamin supplements business.

GSK and Pfizer would open negotiations with Unilever’s boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds, a source familiar with Pfizer’s strategy said.

The source called the business a “legitimate standalone candidate”, adding its market value could rise to almost $100 billion once the business was spun out and listed.

“Right now there is more value in a spin-off but if Unilever is ready to go north of 60 billion pounds then a dialogue could start,” he said.

GSK declined to comment and Pfizer did not immediately respond to a request for comment on the fate of GSK’s consumer business.

EXECUTION

GSK laid out plans for a separate listing of the consumer arm in June last year, following pressure from investors to explore a shake-up of the company and focus on its pharmaceuticals business.

A Unilever buyout of the consumer division would be one of the largest ever on the London market, and one of the biggest deals globally since the start of the COVID-19 pandemic.

It would also boost Unilever’s growth strategy, as management has been under pressure to turn around the company’s languishing stock price and cope with high costs and slim margins, but raises questions about its strategy.

Some analysts expressed doubts over Unilever’s ability to sweeten its offer to GSK.

“Given vocal investor concern of late and Unilever’s share price reaction this morning, this could prevent a higher offer from materialising,” said Chris Beckett, head of equity research at Quilter Cheviot.

Reports of buying interest in GSK’s consumer arm, including from private equity players, have been doing the rounds for a while. read more

“It’s a little surprising that (GSK and Pfizer) haven’t ripped Unilever’s arm off at £50bn, as it’s a decent price, with the only question being as to whether it’s the right one,” CMC Markets analyst Michael Hewson said in a note.

“It might be for GlaxoSmithKline and Pfizer, however there is a feeling that for Unilever it could well prove to be too high a price,” Hewson added.

Unilever, which is set to announce an initiative later this month to strengthen its business, said on Monday it was committed to “strict financial discipline” for any acquisitions, adding that such deals would be accompanied by the divestment of lower margin businesses or brands.

($1 = 0.7312 pounds)

Register now for FREE unlimited access to Reuters.com

Register

Reporting by Pushkala Aripaka and Siddharth Cavale in Bengaluru, Keith Weir, Pamela Barbaglia, Carolyn Cohn and Simon Jessop in London and Ludwig Burger in Frankfurt; Editing by Shounak Dasgupta, Jane Merriman and Emelia Sithole-Matarise

Our Standards: The Thomson Reuters Trust Principles.

Read original article here